Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Mater Adult Hospital, South Brisbane

Sir Charles Gairdner Hospital, Nedlands

Karmanos Cancer Institute, Detroit

University Texas Health Science Center at San Antonio (CTRC), San Antonio

Mayo Clinic, Scottsdale

Hospital de clinicas de Porto Alegre, Porto Alegre

Premiere Oncology, Santa Monica

San Diego Pacific Oncology & Hematology Associates, Encinitas

University San Diego Moores Cancer Center, San Diego

Kaiser Permanente, San Diego

SEAROC Cancer Centre S.K. Soni Hospital, Jaipur

Ruby Hall Clinic, Pune

Apollo Hospital, Hyderabad

Tata Memorial Hospital, Mumbai

Kidwai Memorial Institute of Oncology, Bangalore

Apollo Speciality Hospital, Chennai

Chittaranjan National Cancer Institute, Kolkata

Massachusetts General Hospital, Boston

Policlinica Privada Instituto de Medicina Nuclear, Bahía Blanca

Hospital Britanico, Capital Federal

Caici Centro de Asistencia e Investigacion Clinica Integral, Rosario

Hospital del Centrenario, Rosario

Bendigo Health Care Group, Bendigo

Fundacap Pip XII Hospital do Cancer de Barretos, Barretos

Hospital Erasto Gaertner Liga do Combate as Cancer, Curitiba

Associacao Hospital de Caridade Ijui, Ijuí

Hospital Sao Lucas, Porte Alegre

Clinionco-Clinica de Oncologia de Porto Alegre, Porto Alegre

Hosp.das Clinicas da Univ.de Sao Paulo, São Paulo

Instituto do Cancer Aenaldo Vieira de Carvahlo, São Paulo

Instituto Nacional del Cancer Oncology, Santiago

Hospital Carlos Van Buren, Valparaíso

Subodh Mitra Cancer Hospital & Research Centre, Kolkata

Andhra Medical College, Visakhapatnam

Instituto Oncologico De Cordoba, Córdoba

Clinica Universitaria Privada Reina Fabiola, Córdoba